ReviewBlood advances2019
Pathophysiology and management of monoclonal gammopathy of renal significance.
Review in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 71 citations in OpenAlex.
- A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance.Journal of the advanced practitioner in oncology · 2026Article
- Immune-mediated multisystem injury associated with monoclonal gammopathy of clinical significance: a case report.Frontiers in immunology · 2026Article
- Article
- Patient With MGRS/PGNMID Without Detection of a Peripheral Clone: Case Report and Literature Review.Case reports in hematology · 2026Article
- Monoclonal gammopathy of renal significance from a hematologic perspective.Hematology. American Society of Hematology. Education Program · 2025Review
- Pulmonary plasma cell disorders: histopathology, diagnosis, and clinical perspectives.Virchows Archiv : an international journal of pathology · 2025Review
- Article
- Monoclonal Gammopathy of Renal Significance in a Patient With Cryoglobulinemia and Nephrotic Syndrome: A Case Report.Cureus · 2025Article
- Monoclonal gammopathy of renal significance from the perspective of nephrologists.Blood research · 2024Review
- Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights.Journal of cardiovascular development and disease · 2023Review
- Review
- Monoclonal Gammopathy of Renal Significance with Deposits of Infrequent Morphology: Two Case Reports of Light and Heavy Chain Deposition Disease with Atypical Presentation and Literature Review.Medicines (Basel, Switzerland) · 2023Article
- Contemporary Monoclonal Antibody Utilization in Glomerular Diseases.Mayo Clinic proceedings. Innovations, quality & outcomes · 2023Review
- Monoclonal gammopathy of increasing significance: time to screen?Haematologica · 2023Review
- Article
- Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma.Journal of personalized medicine · 2023Review
- Rhabdomyolysis and Acute Renal Dysfunction as Initial Manifestations of Monoclonal Gammopathy of Renal Significance.Cureus · 2023Article
- Review
- Lambda light chain-induced monoclonal gammopathy of renal significance, manifesting with Fanconi Syndrome and osteomalacia.BMC nephrology · 2022Article
- Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.Blood advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Recent years have witnessed a rapid growth in our understanding of the pathogenic property of monoclonal proteins. It is evident that some of these small monoclonal proteins are capable of inducing end-organ damage as a result of their intrinsic physicochemical properties. Hence, an umbrella term, monoclonal gammopathy of clinical significance (MGCS), has been coined to include myriad conditions attributed to these pathogenic proteins. Because kidneys are the most commonly affected organ (but skin, peripheral nerves, and heart can also be involved), we discuss MGRS exclusively in this review. Mechanisms of renal damage may involve direct or indirect effects. Renal biopsy is mandatory and demonstration of monoclonal immunoglobulin in kidney, along with the corresponding immunoglobulin in serum or urine, is key to establish the diagnosis. Pitfalls exist at each diagnostic step, and a high degree of clinical suspicion is required to diagnose MGRS. Recognition of MGRS by hematologists and nephrologists is important, because timely clone-directed therapy improves renal outcomes. Autologous stem cell transplant may benefit selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.